Aspen Confirms ‘Material’ Offers For API Unit Remain Under Consideration
Chemicals And Biochem Segments Saw Increased Sales In FY21; Higher Costs Bit
Executive Summary
Aspen Pharmacare is continuing to ponder offloading another part of its operations, with bids under consideration for its significant API business units. The company only recently sold a basket of products in South Africa to Acino.
You may also be interested in...
Aspen Commits To Further Reshaping If Opportunity Arises
South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”
Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.